Session	SMEs looking for Finance: Pre-seed/Angel/Seed
Title	Engineered enzymes to end alcohol intolerance
Company	Alcolase
Speaker	Mikkel Precht
TRL	TRL 4-7
Keywords feedstock (max 2)	Sugar, phospholipids
Keywords technology (max 2)	Enzyme encapsulation
Keywords End-Product (max 2)	Enzyme supplement

Abstract:

Alcolase is developing a supplement for alcohol intolerance that breaks down alcohol in the stomach, before it is absorbed.

540 million people in Asia carry a gene variant that stops their body clearing acetaldehyde, the toxic byproduct of alcohol. Often called the Asian Flush, it means even one glass of wine can bring flushing, a racing heart and nausea, and long-term health risks rise if they keep drinking. Many drink anyway, because drinking with friends and colleagues is part of life. Nothing on the market is made for them.

Fixing this means solving two problems at once. The liver's own enzymes can't work in the stomach. And stomach acid, salt and proteases destroy unprotected enzymes in seconds. Solve one and not the other, and you get nothing.

We solved both. We built a novel enzyme cascade that works in the stomach. These enzymes get packed inside liposomes. The lipid shell keeps acid and proteases out while alcohol passes straight through. The same shell can protect other fragile actives, a platform beyond alcohol.

Our product patent is pending, with enzyme filings to follow. Alcolase is backed by Ada Ventures, Delphinus Capital, Antler, and a group of angels. We're meeting investors and scale-up partners.